Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 May;23(5):569–577. doi: 10.1111/j.1365-2125.1987.tb03093.x

Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs.

T W Guentert, S Oie, L Paalzow, B M Frey, R Brandt, L J Aarons, M Rowland
PMCID: PMC1386193  PMID: 3593626

Abstract

Mixed micelles (MM) formed from glycocholic acid and lecithin are suited to solubilize lipophilic drugs for intravenous use. To test for possible drug-drug interactions, the protein binding of a series of agents known to bind to different sites on albumin (diazepam, warfarin, ketoprofen, frusemide, probenecid) and additionally (prazosin, quinidine, propranolol) or exclusively (disopyramide) to alpha 1-acid glycoprotein or to transcortin (prednisolone) was determined in the presence and absence of MM. Concentrations of MM, corresponding to the maximum possible plasma concentration achieved by injecting the highest clinical doses of MM into the systemic circulation, had little or no effect on the unbound fractions of drugs known to bind exclusively to albumin. Only at five times higher MM concentrations were the free fractions substantially increased (by up to 45%). Unbound fractions of drugs bound with high affinity but low capacity to alpha 1-acid glycoprotein were increased between 50-85% even at 'therapeutic' doses of MM. The present study suggests that drugs solubilized by MM should be given by slow injection or infusion to patients already receiving drugs which are highly bound to alpha 1-acid glycoprotein.

Full text

PDF
569

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alván G., Bergström K., Borgå O., Iselius L., Pedersen N. Family study of genetic and environmental factors determining the protein binding of propranolol. Eur J Clin Pharmacol. 1983;25(4):437–441. doi: 10.1007/BF00542107. [DOI] [PubMed] [Google Scholar]
  2. Bickel M. H. Binding of chlorpromazine and imipramine to red cells, albumin, lipoproteins and other blood components. J Pharm Pharmacol. 1975 Oct;27(10):733–738. doi: 10.1111/j.2042-7158.1975.tb09392.x. [DOI] [PubMed] [Google Scholar]
  3. Borgå O., Piafsky K. M., Nilsen O. G. Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):539–544. [PubMed] [Google Scholar]
  4. Chen Z., Danon A. Binding of reserpine to plasma albumin and lipoproteins. Biochem Pharmacol. 1979;28(2):267–271. doi: 10.1016/0006-2952(79)90514-8. [DOI] [PubMed] [Google Scholar]
  5. Cowen A. E., Korman M. G., Hofmann A. F., Thomas P. J. Plasma disappearance of radioactivity after intravenous injection of labeled bile acids in man. Gastroenterology. 1975 Jun;68(6):1567–1573. [PubMed] [Google Scholar]
  6. Edwards D. J., Axelson J. E., Slaughter R. L., Elvin A. T., Lalka D. Factors affecting quinidine protein binding in humans. J Pharm Sci. 1984 Sep;73(9):1264–1267. doi: 10.1002/jps.2600730919. [DOI] [PubMed] [Google Scholar]
  7. Frey F. J., Frey B. M., Greither A., Benet L. Z. Prednisolone clearance at steady state in dogs. J Pharmacol Exp Ther. 1980 Nov;215(2):287–291. [PubMed] [Google Scholar]
  8. Gilmore I. T., Thompson R. P. Kinetics of 14C-glycocholic acid clearance in normal man and in patients with liver disease. Gut. 1978 Dec;19(12):1110–1115. doi: 10.1136/gut.19.12.1110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Goolkasian D. L., Slaughter R. L., Edwards D. J., Lalka D. Displacement of lidocaine from serum alpha 1-acid glycoprotein binding sites by basic drugs. Eur J Clin Pharmacol. 1983;25(3):413–417. doi: 10.1007/BF01037957. [DOI] [PubMed] [Google Scholar]
  10. Guentert T. W., Oie S. Effect of plasma protein binding on quinidine kinetics in the rabbit. J Pharmacol Exp Ther. 1980 Oct;215(1):165–171. [PubMed] [Google Scholar]
  11. Hartvig P., Fagerlund C., Emanuelsson B. M. Extractive alkylation of probenecid in plasma and cerebrospinal fluid and determination by electron-capture gas chromatography. J Chromatogr. 1982 Mar 12;228:340–345. doi: 10.1016/s0378-4347(00)80451-x. [DOI] [PubMed] [Google Scholar]
  12. Hinderling P. H., Bres J., Garrett E. R. Protein binding and erythrocyte partitioning of disopyramide and its monodealkylated metabolite. J Pharm Sci. 1974 Nov;63(11):1684–1690. doi: 10.1002/jps.2600631103. [DOI] [PubMed] [Google Scholar]
  13. Hobbelen P. M., Coert A., Geelen J. A., van der Vies J. Interactions of steroids with serum lipoproteins. Biochem Pharmacol. 1975 Jan 15;24(2):165–172. doi: 10.1016/0006-2952(75)90273-7. [DOI] [PubMed] [Google Scholar]
  14. Huang J. D., Oie S. Effect of altered disopyramide binding on its pharmacologic response in rabbits. J Pharmacol Exp Ther. 1982 Nov;223(2):469–471. [PubMed] [Google Scholar]
  15. Jonas A. Interaction of bovine serum high density lipoprotein with mixed vesicles of phosphatidylcholine and cholesterol. J Lipid Res. 1979 Sep;20(7):817–824. [PubMed] [Google Scholar]
  16. Korman M. G., LaRusso N. F., Hoffman N. E., Hofmann A. F. Development of an intravenous bile acid tolerance test. Plasma disappearance of cholylglycine in health. N Engl J Med. 1975 Jun 5;292(23):1205–1209. doi: 10.1056/NEJM197506052922302. [DOI] [PubMed] [Google Scholar]
  17. Lemaire M., Tillement J. P. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol. 1982 Nov;34(11):715–718. doi: 10.1111/j.2042-7158.1982.tb06206.x. [DOI] [PubMed] [Google Scholar]
  18. Lima J. J., Salzer L. B. Contamination of albumin by alpha 1-acid glycoprotein. Biochem Pharmacol. 1981 Sep 15;30(18):2633–2636. doi: 10.1016/0006-2952(81)90596-7. [DOI] [PubMed] [Google Scholar]
  19. McElnay J. C., D'Arcy P. F. Protein binding displacement interactions and their clinical importance. Drugs. 1983 May;25(5):495–513. doi: 10.2165/00003495-198325050-00003. [DOI] [PubMed] [Google Scholar]
  20. Müller W. E., Stillbauer A. E. Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid). Naunyn Schmiedebergs Arch Pharmacol. 1983 Mar;322(2):170–173. doi: 10.1007/BF00512392. [DOI] [PubMed] [Google Scholar]
  21. Nilsen O. G., Jacobsen S. The binding of quinidine to protein fractions of normal human sera. Biochem Pharmacol. 1975 May 1;24(9):995–998. doi: 10.1016/0006-2952(75)90434-7. [DOI] [PubMed] [Google Scholar]
  22. Norris R. L., Ahokas J. T., Ravenscroft P. J., Henry M. Binding of disopyramide to alpha 1-acid glycoprotein in plasma measured by competitive equilibrium dialysis. J Pharm Sci. 1984 Jun;73(6):824–826. doi: 10.1002/jps.2600730630. [DOI] [PubMed] [Google Scholar]
  23. Owens S. M., Mayersohn M., Woodworth J. R. Phencyclidine blood protein binding: influence of protein, pH and species. J Pharmacol Exp Ther. 1983 Sep;226(3):656–660. [PubMed] [Google Scholar]
  24. Piafsky K. M., Borgá O., Odar-Cederlöf I., Johansson C., Sjöqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978 Dec 28;299(26):1435–1439. doi: 10.1056/NEJM197812282992604. [DOI] [PubMed] [Google Scholar]
  25. Pike E., Skuterud B., Kierulf P., Lunde P. K. Significance of lipoproteins in serum binding variations of amitriptyline, nortriptyline, and quinidine. Clin Pharmacol Ther. 1982 Nov;32(5):599–606. doi: 10.1038/clpt.1982.209. [DOI] [PubMed] [Google Scholar]
  26. Reidenberg M. M., Drayer D. E. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet. 1984 Jan;9 (Suppl 1):18–26. doi: 10.2165/00003088-198400091-00003. [DOI] [PubMed] [Google Scholar]
  27. Rubin P., Blaschke T. Prazosin protein binding in health and disease. Br J Clin Pharmacol. 1980 Feb;9(2):177–182. doi: 10.1111/j.1365-2125.1980.tb05830.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sager G., Nilsen O. G., Jacobsen S. Variable binding of propranolol in human serum. Biochem Pharmacol. 1979 Mar 15;28(6):905–911. doi: 10.1016/0006-2952(79)90374-5. [DOI] [PubMed] [Google Scholar]
  29. Scherphof G., Morselt H. On the size-dependent disintegration of small unilamellar phosphatidylcholine vesicles in rat plasma. Evidence of complete loss of vesicle structure. Biochem J. 1984 Jul 15;221(2):423–429. doi: 10.1042/bj2210423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sjöholm I., Ekman B., Kober A., Ljungstedt-Påhlman I., Seiving B., Sjödin T. Binding of drugs to human serum albumin:XI. The specificity of three binding sites as studied with albumin immobilized in microparticles. Mol Pharmacol. 1979 Nov;16(3):767–777. [PubMed] [Google Scholar]
  31. Sudlow G., Birkett D. J., Wade D. N. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol. 1976 Nov;12(6):1052–1061. [PubMed] [Google Scholar]
  32. Takahashi Y., Uruno K., Kimura S. Vitamin E binding proteins in human serum. J Nutr Sci Vitaminol (Tokyo) 1977;23(3):201–209. doi: 10.3177/jnsv.23.201. [DOI] [PubMed] [Google Scholar]
  33. Tinguely D., Baumann P., Conti M., Jonzier-Perey M., Schöpf J. Interindividual differences in the binding of antidepressives to plasma proteins: the role of the variants of alpha 1-acid glycoprotein. Eur J Clin Pharmacol. 1985;27(6):661–666. doi: 10.1007/BF00547045. [DOI] [PubMed] [Google Scholar]
  34. Yacobi A., Lampman T., Levy G. Frequency distribution of free warfarin and free phenytoin fraction values in serum of healthy human adults. Clin Pharmacol Ther. 1977 Mar;21(3):283–286. doi: 10.1002/cpt1977213283. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES